Teleflex (NYSE:TFX) announced today that it entered into a new agreement with FundamentalVR over integration for medical simulation.
Wayne, Pennsylvania-based Teleflex’s agreement with FunamentalVR, a leader in virtual reality (VR) integration for medical simulation, will provide Teleflex with a VR training platform to accelerate the effective use of its UroLift 2 system.
UroLift 2, a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH, commonly known as enlarged prostate), is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 45 years or older (50 years outside the U.S.).
UroLift permanent implants can be delivered during an outpatient procedure and relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue.
According to a news release, the VR platform integrates tactile feedback and a digital representation of UroLift…